NCT03580239 is a Phase 3 clinical trial of Everolimus in Prostate Cancer, sponsored by Tianjin Medical University Second Hospital.

Who is sponsoring NCT03580239?

NCT03580239 is sponsored by Tianjin Medical University Second Hospital.

What drugs are being tested in NCT03580239?

Interventions in NCT03580239: Everolimus, Placebo.

What condition does NCT03580239 study?

NCT03580239 studies Prostate Cancer.

Is NCT03580239 still recruiting?

NCT03580239 is currently status unknown. Last updated 9 July 2018.

Last reviewed 2018-07-09 · How we verify

NCT03580239

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Status unknown Phase 3 Last updated 9 July 2018

What this trial tests

Phase 3 trial testing Everolimus in Prostate Cancer in 120 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
31 January 2023

1 December 2023

Quick facts

Lead sponsor	Tianjin Medical University Second Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 January 2019
Primary completion	31 January 2023
Estimated completion	1 December 2023
Sites	4 locations across China

Drugs / interventions tested

Everolimus (everolimus) — full drug profile →
Placebo

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Tianjin Medical University Second Hospital

Who can join

Adults 18 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives.
Wang W, Bai L, Li W, Cui J. · · 2020 · cited 86× · PMID 33364199 · DOI 10.3389/fonc.2020.605154
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, Álvarez-Gómez RM, et al · · 2022 · cited 60× · PMID 35422101 · DOI 10.1038/s41391-022-00537-2
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E, Giantulli S, Sciarra A, Silvestri I. · · 2023 · cited 52× · PMID 36768370 · DOI 10.3390/ijms24032046
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.
Turnham DJ, Bullock N, Dass MS, Staffurth JN, et al · · 2020 · cited 52× · PMID 33105713 · DOI 10.3390/cells9112342
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment.
Li D, Xu W, Chang Y, Xiao Y, et al · · 2023 · cited 21× · PMID 37294106 · DOI 10.3724/abbs.2023092
Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
Davoodi-Moghaddam Z, Jafari-Raddani F, Delshad M, Pourbagheri-Sigaroodi A, et al · · 2023 · cited 14× · PMID 37594532 · DOI 10.1007/s00432-023-05277-x
Leveraging altered lipid metabolism in treating B cell malignancies.
Lee J, Mani A, Shin MJ, Krauss RM. · · 2024 · cited 11× · PMID 38964473 · DOI 10.1016/j.plipres.2024.101288
Is Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer.
Nassar AF, Nie X, Zhang T, Yeung J, et al · · 2024 · cited 2× · PMID 38921447 · DOI 10.3390/metabo14060312

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Tianjin Medical University Second Hospital trials

Trials by the same sponsor.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03580239 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
Last refreshed: 9 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03580239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing